{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:25:10Z","timestamp":1788881110144,"version":"build-2803163510"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Racial and ethnic disparities in access to treatment and quality of treatment for opioid use disorder (OUD) have been identified in usual care settings. In contrast, disparities in treatment quality within clinical trials are relatively unexamined.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate racial and ethnic differences in the dose of opioid agonist treatment for OUD in the first 4 weeks of treatment in clinical trials.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study performed analysis of the methadone and buprenorphine treatment arms of 3 trials conducted by the National Institute on Drug Abuse Clinical Trials Network between May 2006, and January 31, 2017, at multiple Clinical Trials Network sites across the US. Trial participants who were randomized to and initiated buprenorphine or methadone treatment and who identified as Hispanic, non-Hispanic Black, or non-Hispanic White were included in the present study. Data were analyzed from November 1, 2023, to August 5, 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Combined race and ethnicity as self-classified by the patient at trial enrollment.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The maximum daily dose of buprenorphine or methadone received in each week for the first 4 weeks of treatment. The mean dose and the percentage of patients receiving a higher dose (buprenorphine \u2265<\/jats:italic>16 mg and methadone \u2265<\/jats:italic>60 mg) were compared across race and ethnicity groups.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 1748 patients (1263 who initiated buprenorphine and 485 who initiated methadone treatment) were included in the analysis (1168 [66.8%] male; median age, 33 [IQR, 26-45] years). Of these, 138 patients (7.9%) identified as Black, 273 (15.6%) as Hispanic, and 1337 (76.5%) as White. In week 4, Black patients received buprenorphine doses 2.5 (95% CI \u22124.6 to \u22120.5) mg lower and methadone doses 16.7 (95% CI, \u221230.7 to \u22122.7) mg lower compared with White patients, after standardizing by age and sex. In week 4, the percentage of patients receiving a higher dose of medication (buprenorphine \u2265<\/jats:italic>16 mg; methadone \u2265<\/jats:italic>60 mg) was 16.9 (95% CI, \u221231.9 to \u22121.9) points lower for Black patients compared with White patients. Hispanic and White patients received similar buprenorphine doses; Hispanic patients received lower methadone doses than White patients.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of data from 3 clinical trials, White patients generally received higher doses of medication than Black patients. Future research is needed to understand the mechanisms of and interventions to reduce disparities in OUD treatment quality and how such disparities impact generalizability of trial results.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.36612","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T15:31:09Z","timestamp":1728055869000},"page":"e2436612","source":"Crossref","is-referenced-by-count":11,"title":["Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity"],"prefix":"10.1001","volume":"7","author":[{"given":"Rachael K.","family":"Ross","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shodai","family":"Inose","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matisyahu","family":"Shulman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University Irving Medical Center, Columbia University, New York, New York"},{"name":"New York State Psychiatric Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University Irving Medical Center, Columbia University, New York, New York"},{"name":"New York State Psychiatric Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Zalla","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Kathleen","family":"Burlew","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara E.","family":"Rudolph","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"11","key":"zoi241076r2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jama.281.11.1000","article-title":"Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.","volume":"281","author":"Strain","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"zoi241076r3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial.","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"2","key":"zoi241076r4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"zoi241076r6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/add.14522","article-title":"What should clinicians do as fentanyl replaces heroin?","volume":"114","author":"Bisaga","year":"2019","journal-title":"Addiction"},{"key":"zoi241076r7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.29245\/2578-2959\/2023\/1.1263","article-title":"Racial disparities in opioid use disorder and its treatment: a review and commentary on the literature.","volume":"7","author":"Lynch","year":"2023","journal-title":"J Ment Health Clin Psychol."},{"key":"zoi241076r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108454","article-title":"Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder.","volume":"131","author":"Rosenthal","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"zoi241076r9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jsat.2018.10.006","article-title":"Evidence-based treatment for opioid use disorders: a national study of methadone dose levels, 2011-2017.","volume":"96","author":"D\u2019Aunno","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"zoi241076r10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","article-title":"Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from Starting Treatment With Agonist Replacement Therapies (START).","volume":"74","author":"Potter","year":"2013","journal-title":"J Stud Alcohol Drugs"},{"issue":"2","key":"zoi241076r11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cct.2010.01.003","article-title":"A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology.","volume":"31","author":"Weiss","year":"2010","journal-title":"Contemp Clin Trials"},{"issue":"10118","key":"zoi241076r12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"zoi241076r13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamapsychiatry.2023.3596","article-title":"Individual-level risk prediction of return to use during opioid use disorder treatment.","volume":"81","author":"Luo","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"zoi241076r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109609","article-title":"Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.","volume":"239","author":"Rudolph","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"zoi241076r15","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1080\/01419870.2016.1140793","article-title":"The multiple dimensions of race.","volume":"39","author":"Roth","year":"2016","journal-title":"Ethn Racial Stud"},{"issue":"3","key":"zoi241076r16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/aje\/kwad209","article-title":"The importance of equity value judgments and estimator-estimand alignment in measuring disparity and identifying targets to reduce disparity.","volume":"193","author":"Chang","year":"2024","journal-title":"Am J Epidemiol"},{"issue":"2","key":"zoi241076r17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/EDE.0000000000001319","article-title":"Meaningful causal decompositions in health equity research: definition, identification, and estimation through a weighting framework epidemiology.","volume":"32","author":"Jackson","year":"2021","journal-title":"Epidemiology"},{"issue":"3","key":"zoi241076r18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7326\/M23-2430","article-title":"Responding to reviewers and editors about statistical significance testing.","volume":"177","author":"Savitz","year":"2024","journal-title":"Ann Intern Med"},{"key":"zoi241076r21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on P values: context, process, and purpose.","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Statist"},{"issue":"1","key":"zoi241076r22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2202\/1557-4679.1043","article-title":"Targeted maximum likelihood learning.","volume":"2","author":"Van Der Laan","year":"2006","journal-title":"Int J Biostat"},{"key":"zoi241076r23","doi-asserted-by":"publisher","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner.","volume":"6","author":"van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"8","key":"zoi241076r24","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.90.8.1212","article-title":"Levels of racism: a theoretic framework and a gardener\u2019s tale.","volume":"90","author":"Jones","year":"2000","journal-title":"Am J Public Health"},{"issue":"16","key":"zoi241076r27","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1073\/pnas.1516047113","article-title":"Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between Blacks and Whites.","volume":"113","author":"Hoffman","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"zoi241076r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmqr.2023.100298","article-title":"\u201cA lack of empathy:\u201d a qualitative study of Black people seeking treatment for opioid use disorder.","volume":"4","author":"Khatri","year":"2023","journal-title":"SSM Qual Res Health"},{"issue":"4","key":"zoi241076r29","first-page":"792","article-title":"Perception of racism explains the difference between Blacks\u2019 and Whites\u2019 level of healthcare trust.","volume":"16","author":"Adegbembo","year":"2006","journal-title":"Ethn Dis"},{"key":"zoi241076r30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1037\/0735-7028.32.6.555","article-title":"Cultural mistrust: an important psychological construct for diagnosis and treatment of African Americans.","volume":"32","author":"Whaley","year":"2001","journal-title":"Prof Psychol Res Pr"},{"issue":"19","key":"zoi241076r32","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","article-title":"Racial inequality in receipt of medications for opioid use disorder.","volume":"388","author":"Barnett","year":"2023","journal-title":"N Engl J Med"},{"key":"zoi241076r1","volume-title":"Medications for Opioid Use Disorder Save Lives","year":"2019"},{"key":"zoi241076r19","author":"Kenneth","year":"2021"},{"key":"zoi241076r25","volume-title":"The Stigma of Addiction: An Essential Guide","author":"Sonia","year":"2019"},{"key":"zoi241076r31","author":"Smedley","year":"2003"},{"key":"zoi241076r5","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. TIP 63. Updated 2021. Accessed October 2, 2023. https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document\/PEP21-02-01-002"},{"key":"zoi241076r20","unstructured":"International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Updated January 2024. Accessed March 18, 2024. https:\/\/icmje.org\/recommendations\/"},{"key":"zoi241076r26","unstructured":"Boyd? RW, Lindo? EG, Weeks? LD, McLemore? MR. On racism: a new standard for publishing on racial health inequities. July 2, 2020. Accessed July 10, 2024. https:\/\/www.healthaffairs.org\/content\/forefront\/racism-new-standard-publishing-racial-health-inequities"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824382\/ross_2024_oi_241076_1727454029.46115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T15:31:13Z","timestamp":1728055873000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.36612","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}